
- The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health shares traded in a range of $10.07 to $10.19 on a day volume of 3.81 million shares, closed regular trading session at $10.1.
- The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to aTyr Pharma’s (NASDAQ:LIFE) lead therapeutic candidate, efzofitimod (ATYR1923), for the treatment of pulmonary sarcoidosis, a major form of interstitial lung disease. aTyr shares traded in a range of $3.58 to $3.87 on a day volume of 643.67 thousand shares, closed regular trading session at $3.65. The company shares are currently trading at $3.73, up 2.19 percent in the after-hours trading session.